Life Sciences & Healthcare Innovation Hub

Our innovation hub for life sciences and healthcare is a demonstration of Cooley’s enduring commitment to the industry. It serves as a centralized point from which to access the insights and unparalleled experience of leading legal thinkers from across the firm and around the world.

Cooley Life Sciences Team Named by Law360 as a Practice Group of the Year for the Third Consecutive Year

Law360 has recognized Cooley as Practice Group of the Year in two areas: life sciences and technology. This marks the third consecutive year that Law360 has cited Cooley as a leading life sciences practice group based on its capacity for delivering client results across the life sciences industry sector.

January 21, 2025

Life Sciences Litigation: Biosimilars, 2024 Year in Review

Cooley lawyers recap the most important biosimilars cases, decisions, industry developments and government initiatives from 2024, as well as what to watch for in 2025.

January 23, 2025

ArsenalBio Closes Oversubscribed $325 Million Series C

A Cooley team advised Arsenal Biosciences, a clinical-stage programmable cell therapy company, on the close of its oversubscribed $325 million Series C financing round.

September 4, 2024

Tempus AI Announces $410.7 Million IPO

Cooley advised Tempus AI, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, on its $410.7 million initial public offering.

June 13, 2024

Cooley Defeats Preliminary Injunction for Liquidia in Litigation With United Therapeutics

A Cooley team successfully defeated a preliminary injunction filed by United Therapeutics that sought to block the launch of client Liquidia’s Yutrepia (treprostinil) inhalation powder for the treatment of pulmonary hypertension associated with interstitial lung disease.

June 3, 2024